| 1 | xgx pharma is a | | | | | | | 2 | 1.30% |
| 2 | sales of specialty gx | | | | | | | 1 | 0.65% |
| 3 | is engaged in licensing | | | | | | | 1 | 0.65% |
| 4 | pharma is engaged in | | | | | | | 1 | 0.65% |
| 5 | xgx pharma is engaged | | | | | | | 1 | 0.65% |
| 6 | pharmaceutical platform creating value | | | | | | | 1 | 0.65% |
| 7 | platform creating value for | | | | | | | 1 | 0.65% |
| 8 | creating value for all | | | | | | | 1 | 0.65% |
| 9 | regulatory and commercial specialists | | | | | | | 1 | 0.65% |
| 10 | medical regulatory and commercial | | | | | | | 1 | 0.65% |
| 11 | of medical regulatory and | | | | | | | 1 | 0.65% |
| 12 | dedicated team of medical | | | | | | | 1 | 0.65% |
| 13 | team of medical regulatory | | | | | | | 1 | 0.65% |
| 14 | value for all our | | | | | | | 1 | 0.65% |
| 15 | a highly experienced and | | | | | | | 1 | 0.65% |
| 16 | by a highly experienced | | | | | | | 1 | 0.65% |
| 17 | led by a highly | | | | | | | 1 | 0.65% |
| 18 | company led by a | | | | | | | 1 | 0.65% |
| 19 | held company led by | | | | | | | 1 | 0.65% |
| 20 | privately held company led | | | | | | | 1 | 0.65% |
| 21 | a privately held company | | | | | | | 1 | 0.65% |
| 22 | capabilities with an agile | | | | | | | 1 | 0.65% |
| 23 | engaged in licensing development | | | | | | | 1 | 0.65% |
| 24 | licensing development distribution and | | | | | | | 1 | 0.65% |
| 25 | in licensing development distribution | | | | | | | 1 | 0.65% |
| 26 | commercial approach we have | | | | | | | 1 | 0.65% |
| 27 | and our strong medical | | | | | | | 1 | 0.65% |
| 28 | insight and our strong | | | | | | | 1 | 0.65% |
| 29 | market insight and our | | | | | | | 1 | 0.65% |
| 30 | unique market insight and | | | | | | | 1 | 0.65% |
| 31 | our unique market insight | | | | | | | 1 | 0.65% |
| 32 | combine our unique market | | | | | | | 1 | 0.65% |
| 33 | we combine our unique | | | | | | | 1 | 0.65% |
| 34 | an agile commercial approach | | | | | | | 1 | 0.65% |
| 35 | agile commercial approach we | | | | | | | 1 | 0.65% |
| 36 | approach we have a | | | | | | | 1 | 0.65% |
| 37 | gx pharmaceutical platform creating | | | | | | | 1 | 0.65% |
| 38 | we have a strong | | | | | | | 1 | 0.65% |
| 39 | in the nordic region | | | | | | | 1 | 0.65% |
| 40 | operate in the nordic | | | | | | | 1 | 0.65% |